The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck’s LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca’s AZD0780, Aqur’s AQR-008, and Others | DelveInsight

The PCSK9 inhibitors market is poised for robust growth, driven by the rising prevalence of hypercholesterolemia, dyslipidemia, and cardiovascular diseases worldwide. Growing adoption of advanced lipid-lowering therapies among patients unable to achieve adequate LDL-C control with statins is further supporting market expansion. The recent approval of Merck’s LIPFENDRA and the emergence of next-generation oral PCSK9 inhibitor drugs, including, AstraZeneca’s AZD0780 and Aqur Biosciences’ AQR-008 is expected to broaden treatment options and improve adherence.

LAS VEGAS, Sept. 1, 2026 /PRNewswire/ — DelveInsight’s PCSK9 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Dyslipidemia, Hypercholesterolemia (Familial + Non-Familial), ASCVD, Coronary Revascularization (CABG and PCI), ACS (Acute Myocardial Infarction & Unstable Angina), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging PCSK9 targeted therapies, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the PCSK9 Targeted Therapies Market Report

• The PCSK9 inhibitors market was found to be USD 3 billion in the 7MM in 2025.
• The United States accounted for the largest PCSK9 inhibitors market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The report provides the total potential number of patients in the indications, such as Dyslipidemia, Hypercholesterolemia (Familial + Non-Familial), ASCVD, Coronary Revascularization (CABG and PCI), ACS (Acute Myocardial Infarction & Unstable Angina), and others.
• Within the familial subtype, HeFH is considerably more prevalent than HoFH. In the US, there were approximately 230K diagnosed prevalent cases of HeFH in 2025.
• Leading PCSK9 targeted therapies companies, such as Hengrui Medicine, Verve Therapeutics, AstraZeneca, Aqur Biosciences, LIB Therapeutics, CVI Pharmaceuticals, and others, are developing novel PCSK9 targeted therapies that can be available in the PCSK9 inhibitors market in the coming years. 
• Some of the key PCSK9 targeted therapies in clinical trials include Recaticimab, VERVE 102, AZD0780, AQR-008, LIB003 (lerodalcibep), CVI-LM001, and others.
• By 2036, among all the therapies, the highest revenue is expected to be generated by LEQVIO.

Discover the difference between LEQVIO vs monoclonal PCSK9 inhibitors for LDL reduction @ https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

Key Factors Driving the PCSK9 Targeted Therapies Market 

• Rising Burden of Cardiovascular Diseases: The growing prevalence of hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), and related cardiovascular conditions is driving demand for effective LDL-C-lowering therapies. The need for better long-term cardiovascular risk management is supporting adoption of PCSK9-targeted treatments.
• Increasing Need for Intensive LDL-C Reduction: A substantial proportion of high-risk patients remain above recommended LDL-C targets despite statin therapy and other lipid-lowering treatments. This unmet need is increasing the use of PCSK9 inhibitors, particularly among patients requiring substantial LDL-C reductions.
• Approval of Merck’s LIPFENDRA: The FDA approval of Merck’s LIPFENDRA (enlicitide) marks a major milestone in the oral PCSK9 inhibitor market, establishing the first approved oral therapy in this class. Its once-daily oral administration could broaden patient acceptance and address adherence barriers associated with injectable PCSK9 therapies, potentially expanding the overall PCSK9 treatment population.
• Advances in PCSK9-Targeted Drug Development: Innovations across monoclonal antibodies, small molecules, oral inhibitors, and RNA-based approaches are broadening the PCSK9 therapeutic landscape. Some of the PCSK9 inhibitors drugs under development include Recaticimab (Hengrui Medicine), VERVE 102 (Verve Therapeutics), AZD0780 (AstraZeneca), AQR-008 (Aqur Biosciences), LIB003 (lerodalcibep; LIB Therapeutics), CVI-LM001 (CVI Pharmaceuticals), and others.

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that oral PCSK9 and gene therapies have a great deal of promise. The approval of LIPFENDRA, and development of Laroprovstat and VERVE-102 have a significant opportunity to reduce patient burden. These emerging therapies offer potential improvements in patient convenience and adherence.

PCSK9 Targeted Therapies Market Analysis

• PCSK9-targeted therapies represent an important class of lipid-lowering therapies (LLTs), primarily used in patients with familial hypercholesterolemia or established ASCVD who need additional LDL-C reduction despite receiving maximally tolerated statin therapy. 
• Since their introduction in 2015, large-scale clinical studies have shown that these therapies can reduce LDL-C levels by approximately 60% and lower cardiovascular event risk by nearly 50% in secondary prevention settings. 
• However, despite their strong clinical efficacy, real-world uptake has remained constrained by high treatment costs, insurance and administrative barriers, and prescriber reluctance.
• REPATHA, developed by Amgen, was among the first PCSK9 inhibitors to enter the market, receiving FDA approval in August 2015 and EMA approval in July 2015 for patients with HeFH, HoFH, and clinical ASCVD requiring additional LDL-C lowering. 
• PRALUENT, developed by Sanofi and Regeneron, followed shortly after, gaining FDA approval in July 2015 and EMA approval in September 2015 for adults with primary hypercholesterolemia, including HeFH and non-familial forms, as well as mixed dyslipidemia.
• Both therapies subsequently expanded their indications following major cardiovascular outcomes trials. The FOURIER trial in 2017 provided evidence supporting REPATHA for cardiovascular risk reduction, while the ODYSSEY Outcomes trial in 2018 supported an expanded indication for PRALUENT to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization.
• The PCSK9 treatment landscape was further strengthened with the introduction of LEQVIO (inclisiran), which received FDA approval in 2021. Unlike conventional PCSK9 monoclonal antibodies, LEQVIO employs small interfering RNA (siRNA) technology to suppress hepatic PCSK9 production, offering a distinct approach to sustained LDL-C reduction.
• Recently, in July 2026, the U.S. FDA has approved Merck’s LIPFENDRA (20 mg tablets) as an adjunct to diet and exercise for lowering LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), marking the first approval of an oral PCSK9 inhibitor and a significant breakthrough in the PCSK9 inhibitor landscape.
• The pipeline is also expanding, with several emerging PCSK9-targeted candidates under development, including Recaticimab from Hengrui Medicine, VERVE-102 from Verve Therapeutics, AZD0780 from AstraZeneca, AQR-008 from Aqur Biosciences, and other novel approaches. 
• Among these, Recaticimab (Hengrui Medicine) represents one of the notable next-generation PCSK9-targeted therapies being evaluated for hypercholesterolemia and cardiovascular risk reduction.

Learn more about the PCSK9 inhibitors brand names @ PCSK9 Inhibitors Names

PCSK9 Targeted Therapies Competitive Landscape

Some of the PCSK9 inhibitors drugs under development include Recaticimab (Hengrui Medicine), VERVE 102 (Verve Therapeutics), AZD0780 (AstraZeneca), AQR-008 (Aqur Biosciences), LIB003 (lerodalcibep; LIB Therapeutics), CVI-LM001 (CVI Pharmaceuticals), and others.

Hengrui Medicine’s Recaticimab is a fully human IgG1 monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By selectively binding to PCSK9, it prevents PCSK9 from interacting with the low-density lipoprotein receptor (LDLR), thereby reducing PCSK9-mediated LDLR degradation. This increases the availability of LDLRs on the cell surface and promotes the clearance of LDL cholesterol (LDL-C) from the bloodstream. Its commercialization introduces an additional therapeutic option for patients requiring LDL-C reduction.

AstraZeneca’s AZD0780 is an investigational oral small-molecule PCSK9 inhibitor designed to address elevated LDL-C levels in patients who do not achieve adequate control with statin therapy alone. AstraZeneca is assessing AZD0780 as both a standalone treatment and as part of fixed-dose combinations with other therapies across its cardiovascular portfolio. The candidate is currently undergoing Phase III clinical development.

Aqur Biosciences’ AQR-008 employs a differentiated mechanism of action by targeting the EGF-A domain of the LDL receptor rather than directly inhibiting PCSK9. By preventing PCSK9 from binding to LDLR, AQR-008 is designed to protect the receptor while potentially preserving PCSK9’s other biological functions, which continue to be investigated. This receptor-focused strategy highlights the evolving PCSK9 inhibitor landscape, with next-generation therapies pursuing alternative mechanisms that could offer greater selectivity, improved safety profiles, and enhanced treatment convenience.

The anticipated launch of these emerging therapies are poised to transform the PCSK9 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PCSK9 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about leading biopharmaceutical companies PCSK9 inhibitors, visit @ PCSK9 Inhibitors List

Recent Developments in the PCSK9 Targeted Therapies Market

• In August 2026, LIB Therapeutics, Inc. announced that the FDA has approved an autoinjector for LEROCHOL (lerodalcibep-liga) Injection 300 mg/1.2 mL, a third-generation PCSK9 inhibitor designed to deliver robust, sustained efficacy through convenient once-monthly, single-injection self-administration, potentially supporting long-term treatment adherence. The FDA also approved an update to LEROCHOL’s prescribing information to reflect its indication for reducing the risk of major adverse cardiovascular events (MACE) in adults through LDL-C lowering, either with statins or with monoclonal antibody PCSK9 inhibitors used as an adjunct to statin therapy.
• In July 2026, Merck announced that the FDA has approved LIPFENDRA (enlicitide) tablets, 20 mg, as an adjunct to diet and exercise for lowering low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA, a novel macrocyclic peptide, is the first FDA-approved oral PCSK9 inhibitor demonstrated to reduce LDL-C, commonly referred to as “bad cholesterol.”
• In July 2026, Evogene Ltd. and ELEO Inc. announced a strategic scientific partnership focused on the discovery and development of next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.

PCSK9 Targeted Therapies Epidemiology Segmentation

The PCSK9 inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of ASCVD, followed by France in 2025, while Spain had the lowest diagnosed prevalent population.

The PCSK9 targeted therapies target patient pool is segmented into:

• Total Cases of Selected Indications for PCSK9-targeted Therapies
• Total Treatment Eligible Cases of Selected Indications for PCSK9-targeted Therapies
• Total Statin-intolerant/Uncontrolled LDL Cases for PCSK9-targeted Therapies

Scope of the PCSK9 Targeted Therapies Market Report

• PCSK9 Targeted Therapies Patient Population Forecast
• PCSK9 Targeted Therapies Therapeutics Market Size
• PCSK9 Targeted Therapies Pipeline Analysis
• PCSK9 Inhibitors Market Size and Trends
• PCSK9 Inhibitors Market Opportunity
• PCSK9 Inhibitors Market Unmet Needs
• KOL’s Views on PCSK9 Targeted Therapies
• PCSK9 Inhibitors Market Access and Reimbursement

Discover PCSK9 inhibitors latest developments 2026 @ Oral PCSK9 Inhibitors in Development 2026

Table of Contents

Related Reports

PCSK9 Inhibitors Clinical Trial Analysis 

PCSK9 Inhibitors Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PCSK9 inhibitors companies, including Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.

Familial Hypercholesterolemia Market

Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key familial hypercholesterolemia companies, including Sanofi, Regeneron Pharmaceuticals, Amgen, Esperion Therapeutics, Aegerion Pharmaceutical, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, and others.

Homozygous Familial Hypercholesterolemia Market

Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key homozygous familial hypercholesterolemia companies, including Arrowhead Pharmaceuticals, Novartis, Alnylam Pharmaceuticals, LIB Therapeutics, and others.

Hypercholesterolemia Market

Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypercholesterolemia companies, including Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Esperion Therapeutics, Inc., Arrowhead Pharmaceuticals, LIB Therapeutics LLC, Medpace, Inc., AstraZeneca, NewAmsterdam Pharma, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-oral-pcsk9-inhibitor-market-enters-high-growth-phase-owing-to-the-approval-of-mercks-lipfendra-and-the-emergence-of-oral-pcsk9-inhibitor-drugs-including-astrazenecas-azd0780-aqurs-aqr-008-and-others–delveinsight-302865821.html

SOURCE DelveInsight Business Research, LLP